Primary Central Nervous System Lymphoma

Watchlist

(log in to enable)

Retrieved

2021-01-23

Source

Orphanet

Trials

—

Genes

TBL1XR1, MTX1, MYD88, IL10, BCL6, CD79B, LAMC2, BCL2, CSF2, MGMT, IGH, PDCD1, BTK, CXCL13, STAT3, CD274, KRT20, HDC, IRF4, MS4A1, CDKN2A, ABCB1, TNFSF13B, SMUG1, MYC, IGHV4-34, SPP1, PDLIM7, TBC1D9, SLC19A1, TNFRSF13B, PIK3CA, PIK3CB, PIM1, PIK3CD, PIK3CG, CXCL12, MME, IL4, MIR21, PDCD1LG2, ETV6, PPP1R9A, CEBPZ, PASK, MIR30D, MALT1, MIR93, GNA13, MIR370, ANP32B, CIB1, TRIM13, CXADRP1, NR1I3, MIR30C1, TOX, LOC102723407, LOC102724971, MTCO2P12, TIMELESS, PROM1, TNFSF13, HRK, NR0B2, KMT2D, MIR30C2, TENM4, IBTK, MIR19B1, CIP2A, RTN4R, RTEL1, ISYNA1, BTG2, EXOSC3, FOXP3, IGK, CCDC8, CARD11, PWWP3A, AZIN2, SAMD14, PDCD4, FOXP1, GADL1, HAVCR1, IRF2BP2, MIRLET7B, MIR155, MIR184, ARHGEF5, FAS, VEGFA, CCR7, IVL, ITGB2, CXCL8, IDH1, HDGF, HCRT, MTOR, EIF4EBP1, EBF1, DSC3, DHFR, DAPK1, CXADR, CDKN1B, MRC1, CDKN1A, CD79A, CD68, CD34, CD19, CASR, CANX, PRDM1, BCR, TNFRSF17, B2M, SERPINC1, ASL, MBP, MSH2, TYRO3, RPS6KA3, TYMS, TP53, TNFAIP3, TNF, TFRC, TCN2, STAT6, SPG7, SLC2A1, ARR3, CCL19, CCL2, S100A10, RPS6KA2, COX2, RPS6KA1, RNU2-1, RFC1, PTPRK, PTPN6, PTGS2, PRKCD, PRKAR1A, PECAM1, NFKBIE, NFKB1, MTR, MTHFR, H3P10

Drugs

Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus, haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate

Interested in hearing about new therapies?

Primary central nervous system lymphoma (PCNSL) is a rare nervous system tumor, predominantly due to diffuse large B-cell lymphoma, that involves brain, leptomeninges, eyes, or rarely spinal cord, in the absence of systemic diffusion at the time of diagnosis. It is characterized by a solitary tumor that, depending on its location, can lead to a variety of symptoms such as headache, nausea, vomiting (and other signs of raised intracranial pressure), focal neurologic deficits, neuropsychiatric and ocular symptoms, seizures and personality changes.